Two possibilities could potentially explain drug sensitivity in these patients: 1) wt-EGFR overexpression is tumorigenic and thus sensitizes tumor cells to TKIs; or 2) tumors are driven by other kinases that can be coincidently inhibited by gefitinib. Here, EGFR is linked to neoplasm.